Mosaic Bioprosthesis, Models 305, 310
Medtronic, Inc. · Decision date Oct 23, 2025
What did the FDA decide?
FDA records P990064/S095 as a supplement to PMA P990064, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 23, 2025.
FDA approval order statement
modifications to the ethylene oxide sterilization cycle and additional sterilizers for the sub-tier supplier of sterile sutures used in valve assembly
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 23, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P990064/S095
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- DYE
- Decision code
- OK30
- Decision date
- Oct 23, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: replacement Heart-valve.
- Applicant
- Medtronic, Inc.
- Product code
- DYE
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P990064/S095 received
Application receipt date recorded by FDA.
P990064/S095 · FDA decision
30-Day Notice
P990064/S093 · Related supplement
Mosaic Bioprosthesis
P990064/S096 · Related supplement
Mosaic Bioprosthesis
P990064/S094 · Related supplement
Mosaic Neo Mitral Bioprosthesis
Timeline entries are records held by MedtechLedger for P990064. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P990064
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Mosaic BioprosthesisP990064/S093 | Medtronic, Inc. | PMA supplement | Nov 10, 2025 | FDA |
Mosaic BioprosthesisP990064/S096 | Medtronic, Inc. | PMA supplement | Feb 12, 2026 | FDA |
Mosaic Neo Mitral BioprosthesisP990064/S094 | Medtronic, Inc. | PMA supplement | Mar 3, 2026 | FDA |
Explore the linked device profile
Other records with product code DYE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Jul 29, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Jun 3, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Apr 16, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Mar 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 1851 E. Deere Ave., Santa Ana, CA, 92705
Sources and methodology
- Original FDA record: P990064/S095
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




